[국제]7,000 people on the second day of new confirmation in Japan…Sanofi, review of competitor vaccine production

[앵커]

The spread of new corona 19 confirmed in Japan, when the emergency was issued, has recorded 7,000 people for the second day, and the spread is not easing.

Sanofi, a French pharmaceutical company that has lagged behind the vaccine development competition, is considering production of a vaccine from another competitor.

Connect with reporters. Reporter Jo Soo-hyun!

First of all, please tell us the situation in Japan in detail.

[기자]

It is a count of the local public broadcaster NHK.

Yesterday, an additional 7,14 people were confirmed across Japan, and the death toll increased by 56.

The number of new confirmed cases was counted to 7,000 on the second day.

As a result, the cumulative confirmed cases in Japan amounted to 325,497 and the cumulative death toll was 4,489.

As the number of confirmed cases continues to increase significantly, the shortage of patient beds is also intensifying.

Japan’s Ministry of Health, Labor and Welfare announced that the number of corona patients in home care surpassed 30,000 for the first time as of the 12th.

This is an increase of 1.7 times compared to the previous week’s announcement.

On the 14th, the Japanese government issued an emergency situation in the metropolitan area on the 8th, and on the 14th, it expanded the emergency situation to 7 local governments.

We will continue to watch the trend over the next week to see how effective it will be.

[앵커]

This time, let’s look at the news about vaccines.

French pharmaceutical company Sanofi, which has entered the competition for vaccine development, could produce vaccines for other competitors?

[기자]

Yes, it was revealed in a local radio interview by a senior member of the French Ministry of Finance and Economy.

At the end of last year, Sanofi, who had failed to launch its own vaccine, started negotiations over a way to instead produce a vaccine from another competitor that has already been tested.

Pfizer-Bioentech vaccine and a vaccine developed by Janssen, a subsidiary of Johnson & Johnson, are in mind.

In response, Sanofi confirmed that “we are considering temporarily adjusting some production steps to support the Corona 19 vaccine manufacturers.”

In addition, the current negotiations are “in the very early stages,” and it has not specifically stated which pharmaceutical companies are considering vaccines.

Sanofi previously collaborated with GlaxoSmithKline in the UK to jointly develop a vaccine, but clinical trials did not elicit a sufficient immune response in adults over 50.

Currently, the phase 2 clinical trial has been restarted, and the plan has been revised to release the vaccine as early as the fourth quarter of this year.

In the meantime, it is noteworthy whether if a competitor’s vaccine is produced, the supply of vaccines that cannot keep up with the demand will be breathless, and other pharmaceutical companies that are lagging behind in vaccine development will also consider such a plan.

This is Soo-Hyun Cho, YTN from the International Department.

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]